Detalhe da pesquisa
1.
Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.
J Vasc Interv Radiol
; 33(8): 964-971.e2, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35490932
2.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280657
3.
Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
J Thromb Thrombolysis
; 52(3): 854-862, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33765243
4.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297397
5.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(5): 655-663, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32251621
6.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature
; 515(7528): 563-7, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428504
7.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
8.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932067
9.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
J Immunol
; 194(3): 950-9, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25539810
10.
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Lancet Oncol
; 17(12): 1683-1696, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27836716
11.
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 17(7): 976-983, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27267608
12.
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.
Lancet Oncol
; 21(3): 343-344, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32950226
13.
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Cancer
; 121(11): 1817-26, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25649370
14.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
; 366(26): 2443-54, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658127
15.
Programmed death ligand-1 expression in non-small cell lung cancer.
Lab Invest
; 94(1): 107-16, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24217091
16.
Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
Cancer Discov
; 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38563600
17.
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
JCO Clin Cancer Inform
; 7: e2200165, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084329
18.
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
J Natl Cancer Inst
; 115(4): 437-446, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36625510
19.
Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay.
Cancer
; 118(6): 1607-18, 2012 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22009766
20.
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.
JTO Clin Res Rep
; 3(8): 100367, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35875467